Jagsonpal Pharma Proposes ₹40 Crore Share Buyback

Jagsonpal Pharmaceuticals has proposed a share buyback of up to 16,00,000 equity shares at ₹250 each, totaling a maximum of ₹40 crore. This tender offer aims to return surplus cash to shareholders, with promoters opting out.

Promoters and the promoter group will not participate in this buyback.

Shareholders will vote on the special resolution via postal ballot and e-voting between March 26, 2026, and April 24, 2026.

Boosting Shareholder Value

This buyback is designed to return surplus cash to shareholders, reflecting the company's financial strength and commitment to increasing shareholder value.

Reducing the number of outstanding shares could boost Earnings Per Share (EPS) for remaining shareholders, potentially making the stock more attractive.

Company Background

Founded in 1978, Jagsonpal Pharmaceuticals is an established Indian company focusing on Gynaecology and Orthopaedics, with additional segments in Dermatology and Paediatrics.

The company has a history of rewarding shareholders with dividends and bonus issues, demonstrating a commitment to efficient capital use. In April 2024, it acquired Yash Pharma's India and Bhutan operations for ₹92.47 crore using its internal cash.

While profit growth has been robust (over 43% CAGR in the last three years), sales growth has been more moderate (around 11.1% over five years).

Jagsonpal has faced some regulatory and tax challenges, including contesting a ₹4.82 crore tax demand and past SEBI actions concerning insider trading allegations.

Impact for Shareholders

Shareholders can tender shares at a premium price of ₹250 each.

The buyback, if approved, will reduce the total number of outstanding equity shares.

This reduction could increase EPS for remaining shareholders.

Funding through internal cash avoids adding to the company's debt.

Key Risks

The buyback requires shareholder approval through e-voting by April 24, 2026.

While promoters are not participating, standard regulatory approvals are implied for this corporate action.

Past SEBI actions, such as insider trading bans and settlements for non-compliance, highlight ongoing governance scrutiny.

The company faces ongoing tax disputes, including a recent ₹4.82 crore demand, though it remains confident in its appeals.

The company's stock price has fallen significantly in the months before this buyback announcement, suggesting investor concerns.

Industry Context

Jagsonpal's buyback mirrors a trend among established pharma firms managing surplus cash. Aurobindo Pharma, for example, approved a ₹750 crore buyback in July 2024 at ₹1,460 per share. Like Jagsonpal, peers such as Mankind Pharma and Aurobindo Pharma have also faced tax disputes, highlighting industry-wide compliance challenges.

Scale of Buyback

The buyback represents 18.35% of the company's paid-up equity share capital and free reserves as of March 31, 2025.

The 16,00,000 shares planned for buyback make up 2.39% of the company's total equity shares as of March 12, 2026.

What to Watch Next

Monitor the shareholder voting outcome by April 24, 2026.

Track the buyback results after e-voting concludes.

Observe how the company balances capital return with addressing sales growth and regulatory matters.

Watch for updates on ongoing tax disputes and their resolution.